Mostrando 6 resultados de: 6
Subtipo de publicación
Article(6)
Área temáticas
Farmacología y terapéutica(3)
Medicina y salud(3)
Microorganismos, hongos y algas(3)
Enfermedades(1)
Fisiología y materias afines(1)
Área de conocimiento
Infección(4)
Biotecnología(2)
Inmunología(2)
Descubrimiento de fármacos(1)
Farmacología(1)
Origen
scopus(6)
An analysis of preclinical efficacy testing of antivenoms for sub-Saharan Africa: Inadequate independent scrutiny and poor-quality reporting are barriers to improving snakebite treatment and management
ArticleAbstract: Background The World Health Organization’s strategy to halve snakebite mortality and morbidity by 20Palabras claves:Autores:Ainsworth S., Casewell N.R., Harrison R.A., Stefanie K. MenziesFuentes:scopusExploring the Utility of Recombinant Snake Venom Serine Protease Toxins as Immunogens for Generating Experimental Snakebite Antivenoms
ArticleAbstract: Snakebite is a neglected tropical disease that causes high rates of global mortality and morbidity.Palabras claves:antivenom, immunogen, neglected tropical diseases, polyclonal antibodies, recombinant expression, serine proteases, snake venom toxin, snakebiteAutores:Ainsworth S., Alomran N., Alsolaiss J., Blundell P., Casewell N.R., Crittenden E., Dawson C.A., Edge R.J., Hall S.R., Harrison R.A., Stefanie K. Menzies, Wilkinson M.C.Fuentes:scopusIn vitro and in vivo preclinical venom inhibition assays identify metalloproteinase inhibiting drugs as potential future treatments for snakebite envenoming by Dispholidus typus
ArticleAbstract: Snakebite envenoming affects more than 250,000 people annually in sub-Saharan Africa. Envenoming byPalabras claves:Boomslang, drugs, Small molecules, snakebite, SVMPAutores:Alsolaiss J., Casewell N.R., Clare R.H., Crittenden E., Edge R.J., Hall S.R., Harrison R.A., Kool J., Marriott A.E., Stefanie K. Menzies, Westhorpe A., Xie C.Fuentes:scopusLivestock herding and fulani ethnicity are a combined risk factor for development of early adverse reactions to antivenom treatment: Findings from a cross-sectional study in Nigeria
ArticleAbstract: Background Adverse reactions to antivenom considerably complicate the clinical management of snakebiPalabras claves:Autores:Abubakar S.B., Durfa N., Habib A.G., Harrison R.A., Lalloo D.G., Nasidi A., Patel R., Stefanie K. Menzies, Thomas A.O., Tianyi F.L., Trelfa A.Fuentes:scopusTwo snakebite antivenoms have potential to reduce Eswatini’s dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing
ArticleAbstract: Background Snakebite is a major public health concern in Eswatini, where treatment relies upon one aPalabras claves:Autores:Alsolaiss J., Casewell N.R., Crittenden E., Edge R.J., Hall S.R., Harrison R.A., Lalloo D.G., Litschka-Koen T., Murray J., Padidar S., Pons J., Shongwe N., Stefanie K. Menzies, Thomas B., Westhorpe A.Fuentes:scopusVirus-like particles displaying conserved toxin epitopes stimulate polyspecific, murine antibody responses capable of snake venom recognition
ArticleAbstract: Antivenom is currently the first-choice treatment for snakebite envenoming. However, only a low propPalabras claves:Autores:Ainsworth S., Alsolaiss J., Casewell N.R., Crittenden E., Dawson C.A., Edge R.J., Hall S.R., Harrison R.A., Stefanie K. Menzies, Wilkinson M.C.Fuentes:scopus